Loading...
Loading...
Shares of
Halozyme Therapeutics, Inc.HALO were trading higher by 0.62 percent during Thursday's afternoon.
Halozyme Therapeutics
disclosed earlier in the day that
AbbVie IncABBV has dosed its first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary
ENHANZE technology.
The initiation of the clinical study triggered an automatic $5 million milestone payment to Halozyme as part of a prior agreement established between the 2 companies.
"We are pleased that the first product candidate with AbbVie has been advanced into clinical testing just seven months after forming our collaboration agreement," said Dr. Helen Torley, president and chief executive officer. "The progress is encouraging as we seek to help an even broader population of patients with our ENHANZE platform."
Shares of AbbVie were trading higher by nearly 2 percent at $58.13.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in